ClinicalTrials.gg
RecruitingNCT07068165IgG4-RDUpdated Dec 30, 2025

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

A Phase 2/3 interventional study of 5mg lenalidomide and 10mg lenalidomide in IgG4 Related Disease, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Peking Union Medical College Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Immunoglobulin G4-Related Disease · Peking Union Medical College Hospital.

Planned enrollment
Largest of 11
198 · median 74
Started
2025
the only one that year
Phase 2/3
2 of 15
1 open now
Registered
13th of 15
by date

Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 13th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

7 of the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and prednisone alone, so as to find new treatment measures for patients with proliferative IgG4-RD.

03

Conditions studied

  • IgG4 Related Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged between 18 and 75 years who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for IgG4-RD;
  2. Patients with active disease: For patients with initial treatment or relapse after drug withdrawal, active disease is defined as having an IgG4-RD Response Index (RI) of at least 2 points in at least one organ at the time of screening; for those experiencing relapse while on treatment, active disease is defined as having an IgG4-RD RI of at least 3 points in at least one organ at the time of screening;
  3. Patients with the clinical subtype of proliferative IgG4-RD;
  4. Patients who have no plans for pregnancy within the next 18 months and who agree to use reliable measures during the study period;

Exclusion criteria

Exclusion Criteria:

  1. IgG4-RD patients with only fibrotic features;
  2. \<1.5×10\^9 /L or count \<100×10\^9/L;
  3. less than 60 ml/ min;
  4. Liver function grade B or above;
  5. Chronic active infection requiring systemic treatment;
  6. Diagnosed with malignant tumor in the past five years;
  7. Patients with a history of thrombosis;
  8. Using biological agents within six months;
  9. Known to be allergic to lenalidomide or thalidomide;
  10. Pregnant or lactating women;
  11. Patients with any other medical conditions or for specific reasons judged by the investigator to be ineligible to participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    5mg lenalidomide group

    Lenalidomide 5mg/d combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/d for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)

    Drug: 5mg lenalidomide

  • Experimental
    10 mg lenalidomide group

    Lenalidomide 10mg/ day combined with prednisone, the initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, then 5mg every 1-2 weeks until withdrawal (within 24 weeks).

    Drug: 10mg lenalidomide

  • Active comparator
    Prednisone monotherapy group

    The initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, followed by 5mg every 1-2 weeks until withdrawal (within 24 weeks).

    Drug: Prednisone monotherapy

Interventions

  • DrugLenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lenalidomide 5mg/d combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/d for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)

  • DrugLenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lenalidomide 10mg/ day combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/ day for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)

  • DrugPrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, followed by 5mg every 1-2 weeks until withdrawal (within 24 weeks).

06

What researchers measure

Primary outcomes

  1. Recurrence rate at 52 weeks

    Time frame: "From enrollment to the end of treatment at 52 weeks

Secondary outcomes

  1. Treatment response rate

    Time frame: At 4, 12, 24, 36, 52 weeks

  2. IgG4 - RD RI change

    Time frame: At 4, 12, 24, 36, 52 weeks

  3. Change of IgG4-RD damage index (DI)

    Time frame: At 4, 12, 24, 36, 52 weeks

  4. physician's overall assessment of disease activity

    Time frame: At 4, 12, 24, 36, 52 weeks

  5. Changes of serum IgG4 levels

    Time frame: At 4, 12, 24, 36, 52 weeks

  6. security

    Use CTCAE V5.0 to record adverse events

    Time frame: At 4, 12, 24, 36, 52 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 16, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Jul 20, 2028
CompletionEst.
Aug 20, 2028
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07068165
Responsible party
Wen Zhang (Vice director of rheumatology department, Peking Union Medical College Hospital) — Principal investigator
First posted
Jul 16, 2025
Start date
Jul 7, 2025
Primary completion
Jul 20, 2028 (estimated)
Completion
Aug 20, 2028 (estimated)
Last update
Dec 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion